Actively Recruiting
Evaluating Azacitidine With or Without Venetoclax as Maintenance Therapy for Acute Myeloid Leukemia Patients in First Remission
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-10-26
788
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining azacitidine with venetoclax compared to azacitidine alone as maintenance therapy for patients with acute myeloid leukemia AML in first complete remission or remission with incomplete count recovery. This phase III, randomized, open-label trial includes patients aged 14 to 74 years and aims to improve disease-free survival among this group. The study also assesses secondary outcomes like overall survival, relapse-free survival, relapse rates, and minimal residual disease status. Participants are randomly assigned to one of two groups. One group receives azacitidine at 50 mgm daily on days 1 to 5 every 6 weeks for up to 12 cycles, while the other group receives the same azacitidine treatment combined with venetoclax 400 mg daily on days 1 to 7 of each cycle. Treatment continues for up to 12 cycles, with cycles repeating every 6 weeks. The study excludes patients with certain AML subtypes and those with positive minimal residual disease. During the study, participants undergo regular monitoring to assess disease status and safety. Key measurements include disease-free survival over two years, overall survival, relapse-free survival, and rates of minimal residual disease conversion over up to five years. Safety is closely observed throughout the treatment period. The total study duration spans from participant enrollment until the study completion date in 2031, with primary outcome data expected by 2030.
CONDITIONS
Brief Title
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
Research Team
H
Hui Wei, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here